Danish Consumer Durables Stock News

Trifork Group (CPSE:TRIFOR) has just posted its Q1 2026 scorecard, with recent quarterly context showing Q4 2025 revenue of €59.1 million, basic EPS of €0.44 and net income of €8.5 million. The trailing twelve months to Q4 2025 came in at €221.2 million of revenue, basic EPS of €0.53 and net income of €10.3 million. Over the past few reported quarters, revenue has moved between €47.2 million and €59.1 million, with basic EPS ranging from a slight loss of €0.01 to €0.63 and net income...

Novozymes (CPSE:NSIS B) has opened Q1 2026 earnings season with recent quarterly revenue between €981.4 million and €1.08 billion over the past six reported periods, while quarterly EPS ranged from €0.26 to €0.40, and trailing twelve month EPS most recently sat at €1.25 on €4.16 billion of revenue. Over that stretch, revenue has moved from €3.83 billion and EPS of €1.10 on a trailing basis in Q4 2024 to €4.16 billion and EPS of €1.25 by Q4 2025. With trailing net profit margin at 14% compared...

Rockwool stock snapshot after recent performance Rockwool (CPSE:ROCK B) has drawn investor attention after a year of mixed share performance, with the stock showing a return of about 0.6% over the past day but a 39% decline over the past year. See our latest analysis for Rockwool. With the share price at DKK180.8, Rockwool’s recent 1 day share price return of 0.56% sits against a weaker trend, including a 90 day share price return of a 21% decline and a 1 year total shareholder return of a...

If you are trying to figure out whether Novo Nordisk is attractively priced or not, the stock's recent moves and current valuation checks give you a lot to work with. The share price recently closed at kr.286.25, with a 7 day return of 8.0%, 30 day return of 20.8%, a year to date return showing a 13.3% decline, and a 1 year return showing a 32.1% decline, which may suggest changing views on both opportunity and risk. Recent headlines have continued to spotlight Novo Nordisk's role in...

Dampskibsselskabet Norden (CPSE:DNORD) lifted its 2026 full year net profit guidance to a range of US$70 million to US$140 million, up from US$30 million to US$100 million, a shift many investors will scrutinize closely. See our latest analysis for Dampskibsselskabet Norden. The upgraded 2026 profit guidance comes as the stock trades at DKK316.0, with a 90-day share price return of 26.91% and a 1-year total shareholder return of 70.98%, suggesting momentum has been building over both shorter...

ALK-Abelló (CPSE:ALK B) has opened 2026 with Q1 revenue of DKK 1.8b and basic EPS of DKK 2, set against trailing twelve month revenue of DKK 6.6b and EPS of about DKK 5.8 as the company builds on a year in which earnings grew 36.6%. Over the past year, revenue has moved from DKK 5.5b to DKK 6.6b and trailing EPS has progressed from roughly DKK 3.7 to DKK 5.8, while net profit margin has lifted from 16.4% to 19.5%. This gives the latest quarter a firm profitability backdrop for investors...

Recent share performance and business profile FLSmidth (CPSE:FLS) has drawn investor attention after a period of weaker share performance, with the stock showing declines over the past week, month and past 3 months despite a positive 1 year total return. The Copenhagen based mining equipment and services company reports annual revenue of DKK 14,612.0 million and net income of DKK 706.0 million, with operations spread across service, product and pumps, cyclones & valves segments worldwide. See...

Q1 earnings highlight Embla Medical hf (CPSE:EMBLA) performance shift Embla Medical hf (CPSE:EMBLA) has drawn fresh attention after reporting first quarter 2026 earnings, with sales of US$232.4 million and net income of US$14.46 million compared with the same period a year earlier. See our latest analysis for Embla Medical hf. At a share price of DKK27.25, Embla Medical hf has seen a 1-day share price return of 1.87%, while its 90-day share price return of 14.04% and 1-year total shareholder...

As the pan-European STOXX Europe 600 Index ended the week broadly flat amid stalled geopolitical negotiations and fluctuating oil prices, investors are keenly observing potential opportunities in undervalued stocks. In this context, identifying stocks that might be priced below their estimated value can be crucial for those looking to capitalize on positive earnings momentum despite broader economic uncertainties.

GN Store Nord A/S ( CPH:GN ) shareholders will have a reason to smile today, with the analysts making substantial...

Aktieselskabet Schouw (CPSE:SCHO) drew investor attention after first quarter 2026 earnings showed lower sales of DKK 7,699 million, higher net income of DKK 165 million, and improved earnings per share. See our latest analysis for Aktieselskabet Schouw. At a share price of DKK680.0, the stock has a 7 day share price return of 5.92% and a 1 year total shareholder return of 22.85%. This suggests momentum has been building as investors react to the Q1 earnings update and the planned BioMar...

Royal Unibrew (CPSE:RBREW) is back in focus after disclosing that its PepsiCo license agreements for Denmark, Finland, and the Baltic states, currently about 13% of net revenue, will expire at the end of 2028. See our latest analysis for Royal Unibrew. Despite the PepsiCo update and a series of recent announcements, including a larger share buyback, AGM approvals and Q1 2026 results, the stock has had a 30 day share price return of a 19.7% decline and a 1 year total shareholder return of a...

Zealand Pharma and Roche have advanced obesity candidate petrelintide into Phase 3 development. Boehringer Ingelheim reported positive Phase III results for obesity drug survodutide, co-invented with Zealand Pharma. Zealand Pharma is eligible for milestone payments and royalties from survodutide, subject to future sales. CPSE:ZEAL is trading at DKK309.0, with the stock down 32.8% year to date and 36.4% over the past 12 months, alongside gains of 39.1% over three years and 57.4% over five...

Recent share moves and business scale Alm. Brand (CPSE:ALMB) has seen mixed returns recently, with the share up 2.9% over the past day but showing declines over the past week, month, and past 3 months. Over longer periods, the stock has delivered a 3.5% 1 year total return and a 44.2% 3 year total return, giving investors context for the recent pullback. The company reported revenue of DKK 13.8b and net income of DKK 1.2b, with both revenue and net income showing annual growth, which helps...

Service resumption to Jersey puts DFDS (CPSE:DFDS) operations back in focus DFDS (CPSE:DFDS) has fully resumed passenger and freight links to Jersey after earlier disruptions from a berthing accident and an engine room fire, and has also announced extra summer day-trips between Jersey and France. See our latest analysis for DFDS. Investors appear to be reassessing DFDS after these operational setbacks were addressed, with a 30 day share price return of 32.51% and year to date gain of 46.85%...

Why Demant Is Back on Value Investors’ Radar Demant (CPSE:DEMANT) has drawn fresh attention after a recent analysis placed it among the most undervalued European stocks, pointing to a sizeable discount to estimated fair value based on discounted cash flows. See our latest analysis for Demant. At a share price of DKK209.0, Demant has seen a 6.85% 1 month share price return. However, the 1 year total shareholder return of 15.79% and 5 year total shareholder return of 35.49% indicate longer term...

The quarterly results for Danske Bank A/S ( CPH:DANSKE ) were released last week, making it a good time to revisit its...

Aktieselskabet Schouw (CPSE:SCHO) has opened Q1 2026 reporting season with mixed trailing numbers, with Q4 2025 revenue of DKK 8.5b and a basic EPS loss of DKK 2.28 against a prior year Q4 EPS of DKK 9.49 on revenue of DKK 8.5b. Over recent quarters, revenue has moved between DKK 7.9b and DKK 9.5b while quarterly EPS has ranged from DKK 4.96 to DKK 15.53 before the latest loss, setting a varied backdrop for how you read this new update. With trailing net margin sitting at 1.9% versus 2.7% a...

Nouvo Nordisk (CPSE:NOVO B) is back in focus after the US rollout of its oral Ozempic tablet, broader GLP-1 access through partnerships with WW International and GoodRx, and an FDA proposal that would curb compounded semaglutide competitors. See our latest analysis for Novo Nordisk. Despite the positive news on oral Ozempic access and supportive FDA signals on compounded GLP 1 competitors, the share price tells a mixed story. A 17.35% 1 month share price return contrasts with a 15.82% year to...

Ørsted (CPSE:ORSTED) has drawn fresh attention after recent share price moves, with the stock showing a mix of shorter term gains and longer term declines that raise questions about how investors are currently valuing its renewable energy business. See our latest analysis for Ørsted. At a latest share price of DKK170.0, Ørsted shows a 90 day share price return of 20.06% and a year to date share price return of 32.81%, while the 3 year total shareholder return of 51.51% and 5 year total...

Brødrene A & O Johansen (CPSE:AOJ B) has opened 2026 with investors focused on how its recent run of quarterly numbers, including Q4 2025 revenue of DKK 1.7 billion, basic EPS of DKK 2.96 and trailing 12 month EPS of DKK 7.37, lines up with a share price sitting at DKK 92. Over the past year, the company has seen total revenue step from DKK 5.4 billion in the 12 months to Q4 2024 to DKK 6.1 billion in the 12 months to Q4 2025. Net income excluding extra items moved from DKK 163.4 million to...

Expanded UK hospital contract shifts attention to ISS (CPSE:ISS) ISS (CPSE:ISS) has expanded its agreement with the Fulham Road Collaborative in the UK, adding a DKK 100 million per year, five-year facility services contract across three major hospital sites. See our latest analysis for ISS. The expanded UK hospital contract arrives while ISS shares trade at DKK238.6, with a 7 day share price return of 4.56% and year to date share price return of 10.67%, alongside a 1 year total shareholder...

Coloplast (CPSE:COLO B) has come back into focus after Biatain Silicone Fit received an Innovative Technology contract from Vizient in the US, shortly after the company lowered its earnings guidance for 2025/26. See our latest analysis for Coloplast. Coloplast shares trade at DKK402.8 after a 1 day share price return of 2.26%. However, the 30 day share price return of 9.03% decline and 1 year total shareholder return of 39.94% decline indicate that momentum has been weak despite the recent...

DSV A/S ( CPH:DSV ) shareholders are probably feeling a little disappointed, since its shares fell 6.4% to kr.1,571 in...